<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet title="?" type="text/xsl" href="rss.xsl"?>
<rss version="2.0">
<channel>
<title>UBS Research: Healthcare</title>
<link>http://clientportal.ibb.ubs.com/portal/index.jsp?page=eqrschstockrschsector&amp;IndCatCode=HCR&amp;MarketCode=GL&amp;MarketCap=X</link>
<description>UBS Research: Healthcare</description>
<language>en</language>
<copyright>Copyright (C) UBS 2009. All rights reserved.</copyright>
<managingEditor>eMarketing@ubs.com</managingEditor>
<webMaster>eMarketing@ubs.com</webMaster>
<pubDate>Fri, 6 Nov 2009</pubDate>
<lastBuildDate>Sat, 7 Nov 2009</lastBuildDate>
<ttl>60</ttl>
<docs>http://clientportal.ibb.ubs.com/portal/index.jsp?page=eqrschrss</docs>
<image>
<url>http://research.ibb.ubs.com:80/images/logo.gif</url>
<title>UBS</title>
<link>http://www.ubs.com</link>
<width>160</width>
<height>44</height>
</image>
<item>
<title><![CDATA[First Read: Biogen Idec Inc. "Updated Tysabri Label; No Major Changes"]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82311|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Biotechnology</li><br><li>Global Healthcare</li><br><li>US Biotechnology</li><br><li>Americas Biotechnology</li><br><li>Americas Healthcare</li><br><li>US Healthcare</li><br><li>North American Biotechnology</li><br><li>North American Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>BIIB.O Biogen Idec Inc.</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Maged Shenouda</author>
<category>BIIB.O</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82311|native|public|20091106221603</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Global Generics "What's the Buzz in Global Generics?" 06-Nov-2009 Goodman]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82308|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Pharmaceuticals</li><br><li>Global Healthcare</li><br><li>Americas Pharmaceuticals</li><br><li>US Pharmaceuticals</li><br><li>Americas Healthcare</li><br><li>US Healthcare</li><br><li>North American Pharmaceuticals</li><br><li>North American Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>TEVA.O Teva Pharmaceuticals</li><br><li>SASY.PA Sanofi-Aventis</li><br><li>REDY.BO Dr. Reddy's Labs</li><br><li>FRX.N Forest Labs</li><br><li>MYL.O Mylan Inc.</li><br><li>WPI.N Watson</li><br><li>CEPH.O Cephalon</li><br><li>SNTS.O Santarus</li><br><li>ENDP.O Endo</li><br></ul><br><em>Subjects</em><br><ul><li>Industry Overview</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Marc Goodman</author>
<category>TEVA.O</category>
<category>SASY.PA</category>
<category>REDY.BO</category>
<category>FRX.N</category>
<category>MYL.O</category>
<category>WPI.N</category>
<category>CEPH.O</category>
<category>SNTS.O</category>
<category>ENDP.O</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82308|native|public|20091106212306</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Resmed "1QFY10 - US growth underpins strong result; but best is yet to come"]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uet11446|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Asia Pacific</li><br><li>Asia Pacific Ex. JP</li><br><li>Australia</li><br><li>Australasia</li><br></ul><br><em>Sectors</em><br><ul><li>Global Advanced Medical Devices</li><br><li>Global Healthcare</li><br><li>Global Medical Products</li><br><li>Asian Pacific Healthcare</li><br><li>Asian Pacific Advanced Medical Devices</li><br><li>Asian Pacific Medical Products</li><br><li>Asian Pacific Ex. JP Healthcare</li><br><li>Asian Pacific Ex. JP Advanced Medical Devices</li><br><li>Asian Pacific Ex. JP Medical Products</li><br><li>Australian Advanced Medical Devices</li><br><li>Australian Healthcare</li><br><li>Australian Medical Products</li><br><li>Australasian Healthcare</li><br><li>Australasian Advanced Medical Devices</li><br><li>Australasian Medical Products</li><br></ul><br><em>Companies</em><br><ul><li>RMD.N Resmed</li><br></ul><br><em>Subjects</em><br><ul><li>Morning Note</li><br></ul>]]></description>
<author>Dan Hurren</author>
<category>RMD.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uet11446|native|public|20091106183859</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Ortho "3Q09 WW performance improves; ASP key question" 06-Nov-2009 Nudell]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82299|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Advanced Medical Devices</li><br><li>Global Healthcare</li><br><li>Global Medical Products</li><br><li>Americas Advanced Medical Devices</li><br><li>Americas Healthcare</li><br><li>Americas Medical Products</li><br></ul><br><em>Companies</em><br><ul><li>SYK.N Stryker</li><br><li>ZMH.N Zimmer</li><br></ul><br><em>Subjects</em><br><ul><li>Industry Overview</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Bruce Nudell, PhD</author>
<category>SYK.N</category>
<category>ZMH.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82299|native|public|20091106173522</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Dong-E E-Jiao "Upgrade on improving fundamentals" (Buy) Zou (Chinese Version)]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=zya02116|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Asia</li><br><li>China</li><br><li>Asia Pacific</li><br><li>Asia Pacific Ex. JP</li><br></ul><br><em>Sectors</em><br><ul><li>Global Pharmaceuticals</li><br><li>Global Healthcare</li><br><li>Asian Pharmaceuticals</li><br><li>Chinese Pharmaceuticals</li><br><li>Asian Healthcare</li><br><li>Chinese Healthcare</li><br><li>Asian Pacific Pharmaceuticals</li><br><li>Asian Pacific Healthcare</li><br><li>Asian Pacific Ex. JP Pharmaceuticals</li><br><li>Asian Pacific Ex. JP Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>000423.SZ Dong-E E-Jiao</li><br></ul><br><em>Subjects</em><br><ul><li>Change in Recommendation</li><br><li>Company Update</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Amy Zou</author>
<category>000423.SZ</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=zya02116|native|public|20091106145430</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[First Read: LifePoint Hospitals "Rev / Cost Controls Drive Q3 Upside" (Neutral)]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82287|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Healthcare Providers</li><br><li>Global Healthcare</li><br><li>Americas Healthcare Providers</li><br><li>US Healthcare Providers</li><br><li>Americas Healthcare</li><br><li>US Healthcare</li><br><li>North American Healthcare</li><br><li>North American Healthcare Providers</li><br></ul><br><em>Companies</em><br><ul><li>LPNT.O LifePoint Hospitals</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Justin Lake, CFA</author>
<category>LPNT.O</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82287|native|public|20091106140557</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Dong-E E-Jiao "Upgrade on improving fundamentals" (Buy) Zou]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uev51579|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Asia</li><br><li>China</li><br><li>Asia Pacific</li><br><li>Asia Pacific Ex. JP</li><br></ul><br><em>Sectors</em><br><ul><li>Global Pharmaceuticals</li><br><li>Global Healthcare</li><br><li>Asian Pharmaceuticals</li><br><li>Chinese Pharmaceuticals</li><br><li>Asian Healthcare</li><br><li>Chinese Healthcare</li><br><li>Asian Pacific Pharmaceuticals</li><br><li>Asian Pacific Healthcare</li><br><li>Asian Pacific Ex. JP Pharmaceuticals</li><br><li>Asian Pacific Ex. JP Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>000423.SZ Dong-E E-Jiao</li><br></ul><br><em>Subjects</em><br><ul><li>Change in Recommendation</li><br><li>Company Update</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Amy Zou</author>
<category>000423.SZ</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uev51579|native|public|20091106115443</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[European Biotechnology "Weekly Valuation & The Week Ahead" 06-Nov-2009 Wales]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69316|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Europe Including UK</li><br><li>Global</li><br></ul><br><em>Sectors</em><br><ul><li>European Biotechnology</li><br><li>Global Biotechnology</li><br><li>European Healthcare</li><br><li>Global Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>GALN.S Galenica</li><br><li>SN.L Smith &amp; Nephew</li><br><li>NOBN.VX Nobel Biocare</li><br><li>SOON.VX Sonova</li><br><li>TECN.S Tecan Group</li><br><li>GDRB.BU Gedeon Richter</li><br><li>GETIb.ST Getinge AB</li><br><li>SHP.L Shire Pharmaceutical</li><br><li>QGEN.F Qiagen</li><br><li>STMN.S Straumann</li><br><li>SYST.VX Synthes Inc</li><br><li>WDH.CO William Demant</li><br><li>LONN.VX Lonza Group</li><br><li>CRCL.AS Crucell</li><br><li>GEN.CO Genmab</li><br><li>ATLN.VX Actelion</li><br><li>BIOX.PA Biomerieux</li><br><li>ELN.I Elan Corp.</li><br><li>FMEG.DE Fresenius Medical</li><br><li>BSLN.S Basilea</li><br><li>ICEL.VI Intercell</li><br><li>DIAS.MI Diasorin</li><br><li>PRON.OL Pronova Biopharma</li><br><li>ROVI.MC Laboratorios Rovi</li><br></ul><br><em>Subjects</em><br><ul><li>Industry Overview</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Martin Wales, PhD</author>
<category>GALN.S</category>
<category>SN.L</category>
<category>NOBN.VX</category>
<category>SOON.VX</category>
<category>TECN.S</category>
<category>GDRB.BU</category>
<category>GETIb.ST</category>
<category>SHP.L</category>
<category>QGEN.F</category>
<category>STMN.S</category>
<category>SYST.VX</category>
<category>WDH.CO</category>
<category>LONN.VX</category>
<category>CRCL.AS</category>
<category>GEN.CO</category>
<category>ATLN.VX</category>
<category>BIOX.PA</category>
<category>ELN.I</category>
<category>FMEG.DE</category>
<category>BSLN.S</category>
<category>ICEL.VI</category>
<category>DIAS.MI</category>
<category>PRON.OL</category>
<category>ROVI.MC</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69316|native|public|20091106110202</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[First Read: Smith & Nephew "Feedback from Q309 results call" (Neutral) Wales]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69312|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Europe Including UK</li><br><li>United Kingdom</li><br><li>Global</li><br><li>UBSW EMEA</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>British Advanced Medical Devices</li><br><li>European Advanced Medical Devices</li><br><li>Global Advanced Medical Devices</li><br><li>European Healthcare</li><br><li>European Medical Products</li><br><li>British Healthcare</li><br><li>British Medical Products</li><br><li>Global Healthcare</li><br><li>Global Medical Products</li><br><li>US Advanced Medical Devices</li><br><li>Americas Advanced Medical Devices</li><br><li>Americas Healthcare</li><br><li>Americas Medical Products</li><br><li>US Healthcare</li><br><li>US Medical Products</li><br><li>North American Healthcare</li><br><li>North American Advanced Medical Devices</li><br><li>North American Medical Products</li><br></ul><br><em>Companies</em><br><ul><li>SN.L Smith &amp; Nephew</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Martin Wales, PhD</author>
<category>SN.L</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69312|native|public|20091106100430</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[European Medtech  "Weekly Valuation & The Week Ahead" 06-Nov-2009 Wales]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69310|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Europe Including UK</li><br><li>Global</li><br><li>Americas</li><br></ul><br><em>Sectors</em><br><ul><li>Global Healthcare</li><br><li>Global Medical Products</li><br><li>Americas Healthcare</li><br><li>Americas Medical Products</li><br></ul><br><em>Companies</em><br><ul><li>GALN.S Galenica</li><br><li>FREG_p.DE Fresenius</li><br><li>CLSGn.F Celesio AG</li><br><li>GN.CO GN Great Nordic</li><br><li>SN.L Smith &amp; Nephew</li><br><li>NOBN.VX Nobel Biocare</li><br><li>SOON.VX Sonova</li><br><li>TECN.S Tecan Group</li><br><li>GETIb.ST Getinge AB</li><br><li>SHP.L Shire Pharmaceutical</li><br><li>QGEN.F Qiagen</li><br><li>STMN.S Straumann</li><br><li>SYST.VX Synthes Inc</li><br><li>WDH.CO William Demant</li><br><li>BIOX.PA Biomerieux</li><br><li>ELN.I Elan Corp.</li><br><li>FMEG.DE Fresenius Medical</li><br><li>DIAS.MI Diasorin</li><br></ul><br><em>Subjects</em><br><ul><li>Industry Overview</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Maja S. Pataki</author>
<category>GALN.S</category>
<category>FREG_p.DE</category>
<category>CLSGn.F</category>
<category>GN.CO</category>
<category>SN.L</category>
<category>NOBN.VX</category>
<category>SOON.VX</category>
<category>TECN.S</category>
<category>GETIb.ST</category>
<category>SHP.L</category>
<category>QGEN.F</category>
<category>STMN.S</category>
<category>SYST.VX</category>
<category>WDH.CO</category>
<category>BIOX.PA</category>
<category>ELN.I</category>
<category>FMEG.DE</category>
<category>DIAS.MI</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69310|native|public|20091106100125</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Novartis "Upgrading PT on upcoming Tasigna data" (Buy) Wenner]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69273|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Switzerland</li><br><li>Europe Including UK</li><br><li>Europe Ex. UK</li><br><li>Global</li><br><li>UBSW EMEA</li><br></ul><br><em>Sectors</em><br><ul><li>Swiss Pharmaceuticals</li><br><li>European Pharmaceuticals</li><br><li>European Ex. UK Pharmaceuticals</li><br><li>Global Pharmaceuticals</li><br><li>Swiss Healthcare</li><br><li>European Healthcare</li><br><li>European Ex. UK Healthcare</li><br><li>Global Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>ROG.VX Roche</li><br><li>NESN.VX Nestlé</li><br><li>NOVN.VX Novartis</li><br><li>AZN.L AstraZeneca</li><br><li>GSK.L GlaxoSmithKline</li><br><li>BMY.N Bristol-Myers</li><br><li>ACL.N Alcon</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Fabian Wenner, PhD</author>
<category>ROG.VX</category>
<category>NESN.VX</category>
<category>NOVN.VX</category>
<category>AZN.L</category>
<category>GSK.L</category>
<category>BMY.N</category>
<category>ACL.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69273|native|public|20091106092845</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[European Bio & MedTech "Changes to Alpha Preferences" 06-Nov-2009 Wales]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69257|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Europe Including UK</li><br><li>Global</li><br></ul><br><em>Sectors</em><br><ul><li>European Biotechnology</li><br><li>Global Biotechnology</li><br><li>European Healthcare</li><br><li>Global Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>GALN.S Galenica</li><br><li>NOBN.VX Nobel Biocare</li><br><li>SOON.VX Sonova</li><br><li>SHP.L Shire Pharmaceutical</li><br><li>QGEN.F Qiagen</li><br><li>STMN.S Straumann</li><br><li>SYST.VX Synthes Inc</li><br><li>WDH.CO William Demant</li><br><li>GEN.CO Genmab</li><br><li>ATLN.VX Actelion</li><br><li>ELN.I Elan Corp.</li><br><li>FMEG.DE Fresenius Medical</li><br><li>BSLN.S Basilea</li><br><li>SCHE.L Southern Cross</li><br></ul><br><em>Subjects</em><br><ul><li>Industry Overview</li><br><li>Market Strategy / Comment</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Martin Wales, PhD</author>
<category>GALN.S</category>
<category>NOBN.VX</category>
<category>SOON.VX</category>
<category>SHP.L</category>
<category>QGEN.F</category>
<category>STMN.S</category>
<category>SYST.VX</category>
<category>WDH.CO</category>
<category>GEN.CO</category>
<category>ATLN.VX</category>
<category>ELN.I</category>
<category>FMEG.DE</category>
<category>BSLN.S</category>
<category>SCHE.L</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69257|native|public|20091106071518</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Smith & Nephew "In line sales, good margins. Q309 results" (Neutral) Wales]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69287|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Europe Including UK</li><br><li>United Kingdom</li><br><li>Global</li><br><li>UBSW EMEA</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>British Advanced Medical Devices</li><br><li>European Advanced Medical Devices</li><br><li>Global Advanced Medical Devices</li><br><li>European Healthcare</li><br><li>European Medical Products</li><br><li>British Healthcare</li><br><li>British Medical Products</li><br><li>Global Healthcare</li><br><li>Global Medical Products</li><br><li>US Advanced Medical Devices</li><br><li>Americas Advanced Medical Devices</li><br><li>Americas Healthcare</li><br><li>Americas Medical Products</li><br><li>US Healthcare</li><br><li>US Medical Products</li><br><li>North American Healthcare</li><br><li>North American Advanced Medical Devices</li><br><li>North American Medical Products</li><br></ul><br><em>Companies</em><br><ul><li>SN.L Smith &amp; Nephew</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Martin Wales, PhD</author>
<category>SN.L</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uer69287|native|public|20091106071110</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Abiomed "Annual Forecast Maintained" (Sell) Schneider]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82263|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Advanced Medical Devices</li><br><li>Global Healthcare</li><br><li>Global Medical Products</li><br><li>US Advanced Medical Devices</li><br><li>Americas Advanced Medical Devices</li><br><li>Americas Healthcare</li><br><li>Americas Medical Products</li><br><li>US Healthcare</li><br><li>US Medical Products</li><br><li>North American Healthcare</li><br><li>North American Advanced Medical Devices</li><br><li>North American Medical Products</li><br></ul><br><em>Companies</em><br><ul><li>ABMD.O Abiomed</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Erik Schneider, CFA</author>
<category>ABMD.O</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82263|native|public|20091106051919</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Cigna "2010 Guidance Generally Conservative" (Buy) Lake]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82261|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Healthcare Providers</li><br><li>Global Healthcare</li><br><li>Americas Healthcare Providers</li><br><li>US Healthcare Providers</li><br><li>Americas Healthcare</li><br><li>US Healthcare</li><br><li>North American Healthcare</li><br><li>North American Healthcare Providers</li><br></ul><br><em>Companies</em><br><ul><li>CI.N Cigna</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Justin Lake, CFA</author>
<category>CI.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82261|native|public|20091106051050</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[King "Solid Transition Quarter; Now We Watch Embeda" (Buy) Goodman]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82257|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Pharmaceuticals</li><br><li>Global Healthcare</li><br><li>Americas Pharmaceuticals</li><br><li>US Pharmaceuticals</li><br><li>Americas Healthcare</li><br><li>US Healthcare</li><br><li>North American Pharmaceuticals</li><br><li>North American Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>KG.N King</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Marc Goodman</author>
<category>KG.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82257|native|public|20091106033538</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Biovail "At this Multiple It's Easy to Keep the Faith" (Buy) Goodman]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82252|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>Canada</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Pharmaceuticals</li><br><li>Global Healthcare</li><br><li>Americas Pharmaceuticals</li><br><li>Canadian Pharmaceuticals</li><br><li>Americas Healthcare</li><br><li>Canadian Healthcare</li><br><li>North American Pharmaceuticals</li><br><li>North American Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>BVF.N Biovail</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Marc Goodman</author>
<category>BVF.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82252|native|public|20091106031703</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Millipore "Solid Third Quarter 2009 Results  " (Buy) de Bruin]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82229|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Advanced Industrial Equipment</li><br><li>Global Biotechnology</li><br><li>Global Healthcare</li><br><li>Global Industrial</li><br><li>Global Industrial Goods &amp; Services</li><br><li>Americas Advanced Industrial Equipment</li><br><li>US Advanced Industrial Equipment</li><br><li>Americas Biotechnology</li><br><li>Americas Healthcare</li><br><li>Americas Industrial</li><br><li>US Industrial</li><br><li>Americas Industrial Goods &amp; Services</li><br><li>US Industrial Goods &amp; Services</li><br><li>North American Industrial</li><br><li>North American Industrial Goods &amp; Services</li><br><li>North American Advanced Industrial Equipment</li><br></ul><br><em>Companies</em><br><ul><li>MIL.N Millipore</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Operating Results</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Derik de Bruin, Ph.D.</author>
<category>MIL.N</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82229|native|public|20091106004747</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
<item>
<title><![CDATA[Intermune "3Q09: Pirfenidone & INFORM-2 Next" (Neutral) Shenouda]]></title>
<link>http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82227|native|public</link>
<description><![CDATA[This document is related to the following:<br><em>Regions</em><br><ul><li>Global</li><br><li>Americas</li><br><li>United States</li><br><li>North America</li><br></ul><br><em>Sectors</em><br><ul><li>Global Biotechnology</li><br><li>Global Healthcare</li><br><li>US Biotechnology</li><br><li>Americas Biotechnology</li><br><li>Americas Healthcare</li><br><li>US Healthcare</li><br><li>North American Biotechnology</li><br><li>North American Healthcare</li><br></ul><br><em>Companies</em><br><ul><li>ITMN.O Intermune</li><br></ul><br><em>Subjects</em><br><ul><li>Company Update</li><br><li>Morning Note</li><br></ul>]]></description>
<author>Maged Shenouda</author>
<category>ITMN.O</category>
<guid isPermaLink="false">http://research.ibb.ubs.com:80/servlet/SrchDoc?rss=uez82227|native|public|20091106003349</guid>
<pubDate>Fri, 6 Nov 2009</pubDate>
</item>
</channel>
</rss>
